A study to investigate the effects of circadian-timed daily administration of bromocriptine-QR [Cycloset] versus placebo in patients with type 2 diabetes whose blood glucose levels were poorly controlled on high dose insulin therapy

Trial Profile

A study to investigate the effects of circadian-timed daily administration of bromocriptine-QR [Cycloset] versus placebo in patients with type 2 diabetes whose blood glucose levels were poorly controlled on high dose insulin therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2015

At a glance

  • Drugs Bromocriptine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2015 New trial record
    • 06 Jun 2015 Results presented at the American Diabetes Association's 75th Scientific Sessions, according to a VeroScience media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top